Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Sitagliptin/Metformin ER vs JANUMET® XR in Healthy Volunteers
NCT06124560Phase 1Completed
- Sponsor
- Galenicum
- Start
- Oct 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sitagliptin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Galenicum. Primary endpoints: Peak Plasma Concentration at 48 hours, Area under the plasma concentration versus time curve 0-t at 48 hours and 1 more. Started Oct 2022; status: completed.
02
Drugs
sitagliptinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06124560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06124560.